|
The 2007 meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, Illinois in June, 2007. The IMF is pleased to bring you this webcast, which includes interviews with a number of the people who presented new findings of interest to the myeloma community.
|
|
Novel Agents
|
|
|
Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. |
|
|
|
|
Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone.
|
|
|
|
|
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma.
|
|
|
|
|
Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses.
|
|
Stem Cell Transplantation
|
|
|
Phase II study of total therapy 3 (TT3) with added bortezomib (V) for multiple myeloma.
|
|
|
|
|
Current status of stem cell transplantation: When? How Many? Allogeneic v Autologous or Both?
|
|
|
|
|
APETHEMA study of high-dose therapy/stem cell support (HDT), including tandem transplant, in primary refractory multiple myeloma
|
|
|
|
|
Outcome of patients relapsing early after autologous stem cell transplantation for multiple myeloma
|
|
Diagnostic Tests
|
|
|
Prediction of response and progression in multiple myeloma (MM) with serum-free light chains (sFLC): Corroboration of the International Myeloma Working Group (IMWG) criteria.
|
|
|
back
print
back to top